Brand names: Nexterone (Amiodarone Hci)
7 interactions on record
7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone.
Source: FDA drug label - nexterone (amiodarone hci)
7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone.
Source: FDA drug label - nexterone (amiodarone hci)
7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone.
Source: FDA drug label - nexterone (amiodarone hci)
Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.
Source: FDA drug label - nexterone (amiodarone hci)
Limit the daily dose of lovastatin to 40 mg.
Source: FDA drug label - nexterone (amiodarone hci)
Antiarrhythmics: The metabolism of quinidine, procainamide, flecainide can be inhibited by amiodarone.
Source: FDA drug label - nexterone (amiodarone hci)
HMG-CoA Reductase Inhibitors: Limit the dose of simvastatin in patients on amiodarone to 20 mg daily.
Source: FDA drug label - nexterone (amiodarone hci)